Skip to main content

Advertisement

SpringerLink
Log in

Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Women with breast cancer that initially involves local lymph nodes have a higher risk for local recurrence or developing metastases. Recent data suggest that germline polymorphism is a significant, previously unrecognized factor in breast cancer progression and metastasis. We assessed the influence of 16 selected common germline polymorphisms in disease-free survival and overall survival among 216 women diagnosed with lymph node-positive breast cancer.

Results

The rare allele of FAS 1377G>A was significantly associated with prolonged disease-free survival (P = 0.012, risk ratio of recurrence (RR) = 0.557, 95% confidence interval (CI) = 0.353–0.878) in univariate analysis. After adjusting for known breast cancer prognostic factors the association remained significant (P = 0.050, RR = 0.500, CI = 0.309–0.809). In overall survival analysis we found a significant association of the FAS 1377G>A (P = 0.040, RR = 0.451, CI = 0.496–1.188) and IL10 592C>A polymorphisms (P = 0.020, RR = 1.707, CI = 1.087–2.680) in the univariate Cox regression. The effect remained statistically significant in the multivariate analysis for the IL10 592C>A polymorphism (P = 0.013, RR 1.841, CI 1.140–2.973). No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival.

Conclusions

Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Balasubramanian SP, Azmy IA, Higham SE, Wilson AG, Cross SS, Cox A, Brown NJ, Reed MW (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6:188

    Article  CAS  PubMed  Google Scholar 

  • Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME (2004) CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 23:3175–3185

    Article  CAS  PubMed  Google Scholar 

  • Campbell IG, Baxter SW, Eccles DM, Choong DY (2002) Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res 4:R14

    Article  PubMed  Google Scholar 

  • Clar H, Langsenlehner U, Krippl P, Renner W, Leithner A, Gruber G, Hofmann G, Yazdani-Biuki B, Langsenlehner T, Windhager R (2008) A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients. Breast Cancer Res Treat 111:449–452

    Article  CAS  PubMed  Google Scholar 

  • Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, Sagiv SK, Teitelbaum SL, Neugut AI, Santella RM (2007) Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 28:2548–2551

    Article  CAS  PubMed  Google Scholar 

  • Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815–3822

    CAS  PubMed  Google Scholar 

  • Gerger A, Langsenlehner U, Renner W, Weitzer W, Eder T, Yazdani-Biuki B, Hofmann G, Samonigg H, Krippl P (2007) A multigenetic approach to predict breast cancer risk. Breast Cancer Res Treat 104:159–164

    Article  CAS  PubMed  Google Scholar 

  • Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, Szkandera J, Samonigg H, Krippl P, Langsenlehner U (2010) Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat 119:701–705

    Article  CAS  PubMed  Google Scholar 

  • Gormus U, Ergen A, Yaylim-Eraltan I, Yilmaz H, Turna A, Bozkurt N, Isbir T (2007) Fas-1377 A/G polymorphism in lung cancer. In Vivo 21:663–666

    CAS  PubMed  Google Scholar 

  • Holliday DL, Hughes S, Shaw JA, Walker RA, Jones JL (2007) Intrinsic gene characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res 9:67

    Article  Google Scholar 

  • Honig SF (1996) Treatment of metastatic disease: hormonal therapy and chemotherapy. In: Harris JR, Lippman M, Morrow M (eds) Diseases of the breast. Lippincott-Raven Publishers, Philadelphia, pp 669–734

    Google Scholar 

  • Howell WM, Rose-Zerilli MJ (2006) Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 5:143–149

    Article  CAS  PubMed  Google Scholar 

  • Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the cancer prevention study II cohort. Breast Cancer Res 8:R22

    Article  PubMed  Google Scholar 

  • Kang S, Dong SM, Seo SS, Kim JW, Park SY (2008) FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 180:1–5

    Article  CAS  PubMed  Google Scholar 

  • Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY, Jeon SW, Lee IT, Choi GS, Jun SH (2008) Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 14:62–66

    Article  CAS  PubMed  Google Scholar 

  • Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Bahadori B, Samonigg H (2003) The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett 201:181–184

    Article  CAS  PubMed  Google Scholar 

  • Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Samonigg H (2004) The 825C>T polymorphism of the G-protein beta-3 subunit gene (GNB3) and breast cancer. Cancer Lett 206:59–62

    Article  CAS  PubMed  Google Scholar 

  • Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Wolf G, Wascher TC, Paulweber B, Weitzer W, Samonigg H (2004) Genetic variants of the sulfotransferase 1A1 and breast cancer risk. Breast Cancer Res Treat 87:19–22

    Article  CAS  PubMed  Google Scholar 

  • Langsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC, Paulweber B, Weitzer W, Samonigg H, Krippl P (2006) The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin Cancer Res 12:1392–1394

    Article  CAS  PubMed  Google Scholar 

  • Le Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE (2004) T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 13:412–415

    CAS  PubMed  Google Scholar 

  • Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH (2003) Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis 8:151–160

    Article  CAS  PubMed  Google Scholar 

  • Lei H, Zaloudik J, Vorechovsky L (2002) Lack of association of the -1171 (5A) allele of the MMP3 promoter with breast cancer. Clin Chem 48:798–799

    CAS  PubMed  Google Scholar 

  • Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, Hunter KW (1998) Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 77:640–644

    Article  CAS  PubMed  Google Scholar 

  • Linnebank M, Semmler A, Moskau S, Smulders Y, Blom H, Simon M (2008) The methylenetetrahydrofolate reductase (MTHFR) variant c.677C>T (A222 V) influences overall survival of patients with glioblastoma multiforme. Neuro Oncol 10:548–552

    Article  CAS  PubMed  Google Scholar 

  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235

    Article  PubMed  Google Scholar 

  • Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 15:61–76

    Article  CAS  PubMed  Google Scholar 

  • Müschen M, Warskulat U, Beckmann MW (2000) Defining CD95 as a tumor suppressor gene. J Mol Med 78:312–325

    Article  PubMed  Google Scholar 

  • Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449–1456

    Article  CAS  PubMed  Google Scholar 

  • Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  • Qui LX, Shi J, Yuan H, Jiang X, Xue K, Pan HF, Li J, Zheng MH (2009) FAS-1377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. Hum Gen 125:431–435

    Article  Google Scholar 

  • Shinohara H, Yagita H, Ikawa Y, Oyaizu N (2000) Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res 60:1766–1772

    CAS  PubMed  Google Scholar 

  • Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330

    CAS  PubMed  Google Scholar 

  • Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96:1030–1036

    Article  CAS  PubMed  Google Scholar 

  • Takayama H, Takakuwa T, Tsujimoto Y, Nonomura N, Okuyama A, Aozasa K (2002) Analysis of Fas gene mutations on laser capture microdissected specimens from renal cell carcinoma. Jpn J Cancer Res 93:1201–1206

    CAS  PubMed  Google Scholar 

  • Ter-Minassian M, Zhai R, Asomaning K, Su L, Zhou W, Liu G, Heist RS, Lynch TJ, Wain JC, Lin X, De Vivo I, Christiani DC (2008) Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 29:2147–2152

    Article  CAS  PubMed  Google Scholar 

  • Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8

    CAS  PubMed  Google Scholar 

  • Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A (2007) The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 8:493–500

    Article  CAS  PubMed  Google Scholar 

  • Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor Gr + CD11b + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409–421

    Article  CAS  PubMed  Google Scholar 

  • Yaylim-Eraltan I, Ergen A, Görmüs U, Arikan S, Küçücük S, Sahin O, Yigit N, Yildiz Y, Isbir T (2009) Breast cancer and cyclin D1 gene polymorphism in Turkish women. In Vivo 23:767–772

    CAS  PubMed  Google Scholar 

  • Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, Spitz MR, Wei Q (2006) Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12:5596–5602

    Article  CAS  PubMed  Google Scholar 

  • Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, Shi Y, Tan W, Zhou Y, Zhao D, Zhang X, Guo Y, Lin D (2007) Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 28:1067–1073

    Article  CAS  PubMed  Google Scholar 

  • Zhang Y, Liu Q, Zhang M, Yu Y, Liu X, Cao X (2009) Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 182:3801–3808

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statements

All authors of the study declare to have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Oncology, Medical University Graz, Auenbruggerplatz 15, 8036, Graz, Austria

    Gudrun Knechtel, Günter Hofmann, Armin Gerger, Joanna Szkandera & Hellmut Samonigg

  2. Clinical Institute of Medical and Laboratory Diagnostics, Medical University Graz, Auenbruggerplatz 15, 8036, Graz, Austria

    Wilfried Renner

  3. Clinic of Therapeutic Radiology and Oncology, Medical University Graz, Auenbruggerplatz 15, 8036, Graz, Austria

    Tanja Langsenlehner

  4. Department of Radiology and Nuclear Medicine, General Hospital Leoben, Vordernbergstrasse 42, 8700, Leoben, Austria

    Gerald Wolf

  5. Department of Internal Medicine, Regional Hospital of Fuerstenfeld, Krankenhausgasse 1, 8280, Fuerstenfeld, Austria

    Peter Krippl

  6. Internal Outpatient Department, Steiermaerkische Gebietskrankenkasse, Josef-Pongratz-Platz 1, 8011, Graz, Austria

    Uwe Langsenlehner

Authors
  1. Gudrun Knechtel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Günter Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Armin Gerger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wilfried Renner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tanja Langsenlehner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joanna Szkandera
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gerald Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hellmut Samonigg
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Peter Krippl
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Uwe Langsenlehner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Armin Gerger.

Additional information

Gudrun Knechtel and Günter Hofmann contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knechtel, G., Hofmann, G., Gerger, A. et al. Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer. J Cancer Res Clin Oncol 136, 1813–1819 (2010). https://doi.org/10.1007/s00432-010-0839-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-010-0839-2

Keywords

Search

Navigation